The computational systems biology services company whose core technology, Virtual Tumour, predicts the effects of combination chemotherapy in pre-clinical and clinical settings and helps its clients to develop better drugs, faster and more cost-effectively, has reported interim results for HY December 2016. Revenue was in line with the comparative period, and we have seen a modest increase in the cost base reflecting increased levels of business development activity as the Company seeks to br
24 Mar 2017
Focus fixed on Virtual Tumour Clinical
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Focus fixed on Virtual Tumour Clinical
Physiomics Plc (PYC:LON) | 1.3 0 13.0% | Mkt Cap: 1.76m
- Published:
24 Mar 2017 -
Author:
Derren Nathan -
Pages:
6
The computational systems biology services company whose core technology, Virtual Tumour, predicts the effects of combination chemotherapy in pre-clinical and clinical settings and helps its clients to develop better drugs, faster and more cost-effectively, has reported interim results for HY December 2016. Revenue was in line with the comparative period, and we have seen a modest increase in the cost base reflecting increased levels of business development activity as the Company seeks to br